What question did this study set out to answer?

To evaluate the clinical efficacy and safety of intralesional epidermal growth factor administration delivered continuously until complete wound closure in patients with chronic diabetic foot ulcers.

February 1, 2009International Wound JournalOpen Access

Intralesional administration of epidermal growth factor‐based formulation (Heberprot‐P) in chronic diabetic foot ulcer: treatment up to complete wound closure

View Full Paper

Ask AI

Bookmark

Authors

JFJosé I Fernández‐MontequínInstituto de Cardiología y Cirugía Cardiovascular BBBlas Y BetancourtUniversity of Florida GLGisselle Leyva‐Gonzalez

Discussion

Member takes

Implication

Pilot study demonstrates high wound closure rates with intralesional epidermal growth factor in chronic diabetic foot ulcers, suggesting an effective strategy to prevent amputations.

Key Points

To evaluate the clinical efficacy and safety of intralesional epidermal growth factor administration delivered continuously until complete wound closure in patients with chronic diabetic foot ulcers.
Conducted a pilot study in 20 diabetic patients presenting with full-thickness lower-extremity ulcers persisting for more than 4 weeks (mean ulcer area: 16.3 ± 21.3 cm²).
Administered intralesional injections of 75 µg Heberprot-P three times per week until complete wound healing was achieved.
Full granulation tissue coverage occurred in 100% of patients (20/20) within 23.6 ± 3.8 days.
Complete wound closure was achieved in 85% of cases (17/20) within 44.3 ± 8.9 days, with zero amputations and only one relapse recorded.
Frequent adverse events included tremors, chills, local pain, odor at the injection site, and localized infection.

Cite This Study

Fernández‐Montequín et al. (2009) studied this question.

synapsesocial.com/papers/6a91096e780df83b8fe1b4e8 https://doi.org/10.1111/j.1742-481x.2008.00561.x

View Full Paper

Ask AI

Bookmark

Implication

Pilot study demonstrates high wound closure rates with intralesional epidermal growth factor in chronic diabetic foot ulcers, suggesting an effective strategy to prevent amputations.

Intralesional administration of epidermal growth factor‐based formulation (Heberprot‐P) in chronic diabetic foot ulcer: treatment up to complete wound closure

Discussion

Member takes

Implication

Key Points

Cite This Study

Intralesional administration of epidermal growth factor‐based formulation (Heberprot‐P) in chronic diabetic foot ulcer: treatment up to complete wound closure

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider